Scholar Rock Holding Corp. (SRRK)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$55.33-1.09%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SRRK
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||
| Revenues | — | — | — | — | 33.2 | 18.8 | 15.4 | 20.5 | 0.0 |
| Total Revenues | — | — | — | — | — | — | — | — | 0.0 |
| Operating Expenses & Income | |||||||||
| R&D Expenses | 207.4 | 208.4 | 184.6 | 121.9 | 124.4 | 108.5 | 74.1 | 54.2 | 36.3 |
| Operating Income | (406.4) | (384.6) | (252.1) | (171.3) | (134.4) | (129.9) | (86.9) | (54.5) | (50.7) |
| Earnings from Continuing Operations | |||||||||
| Interest Expense | — | 6.9 | — | — | — | — | — | — | — |
| Interest & Investment Income | 13.3 | 13.9 | — | — | — | — | — | — | — |
| Other Non-Operating Income / Expenses | (2.2) | 6.7 | 5.8 | 5.5 | (0.1) | (1.9) | 0.4 | 3.5 | 1.4 |
| Net Income | |||||||||
| Net Income | (408.7) | (377.9) | (246.3) | (166.0) | (134.5) | (131.8) | (86.5) | (51.0) | (49.3) |
| Per Share | |||||||||
| Basic EPS | (3.13) | (3.29) | (2.47) | (1.99) | (2.26) | (3.59) | (2.81) | — | — |
| Diluted EPS | (3.13) | (3.29) | (2.47) | (1.99) | (2.26) | (3.59) | (2.81) | — | — |
| Basic Weighted Avg Shares | 130.6 | 114.7 | 99.8 | 83.3 | 59.6 | 36.7 | 30.7 | — | — |
| Diluted Weighted Avg Shares | 130.6 | 114.7 | 99.8 | 83.3 | 59.6 | 36.7 | 30.7 | — | — |
| Supplemental | |||||||||
| EBITDA | — | (383.0) | (250.1) | (168.5) | (131.4) | (127.3) | (85.4) | (53.2) | (49.9) |
| EBIT | (406.4) | (384.6) | (252.1) | (171.3) | (134.4) | (129.9) | (86.9) | (54.5) | (50.7) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.